Report : Asia Pacific Generic Injectables Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Large Molecule Injectables and Small Molecule Injectables), Container Type (Vials, Premix, Prefilled Syringes, Ampoules, and Others), Application (Oncology, Infectious Diseases, Cardiology, Diabetes, Immunology, and Others), and Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Others)
Oncology Segment to Dominate Asia-Pacific Generic Injectables Market during 2019–2028
According to a new market research study on “Asia-Pacific Generic Injectables Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Container Type, Application, and Route of Administration,” is expected to reach US$ 55,751.62 million by 2028 from US$ 26,606.06 million in 2021. The market is estimated to grow at a CAGR of 11.1% from 2021 to 2028. Increasing patent expiry of drugs is the major factor driving the growth of the Asia-Pacific generic injectables market. However, critical inspection system for prefilled injection may hinder the growth of Asia-Pacific generic injectables market. The report provides trends prevailing in the Asia-Pacific generic injectables market along with the drivers and restraints pertaining to the market growth.
The Asia-Pacific generic injectables market is segmented into product type, container type, application, route of administration, and country. The Asia-Pacific generic injectables market, based on product type, has been segmented into large molecule injectable and small molecule injectable. In 2020, the large molecule injectable segment held the largest share Asia-Pacific generic injectables market. The Asia-Pacific generic injectables market, based on container type, has been categorized into vials, premix, prefilled syringes, ampoules, and others. In 2020, the vials segment held the largest share Asia-Pacific generic injectables market. The Asia-Pacific generic injectables market, based on application, has been categorized into oncology, infectious diseases, cardiology, diabetes, immunology, and others. In 2020, the oncology segment held the largest share Asia-Pacific generic injectables market. The Asia-Pacific generic injectables market, based on route of administration, has been categorized into intravenous, intramuscular, subcutaneous, and others. In 2020, the intravenous segment held the largest share Asia-Pacific generic injectables market. Similarly, based on country, the Asia-Pacific generic injectables market is segmented into the China, Japan, India, Australia, South Korea, and the rest of Asia-Pacific. China contributed a substantial share in 2020.
AstraZeneca; Baxter International Inc.; Biocon; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Lupin; Merck & Co., Inc.; Pfizer Inc.; and Viatris Inc are among the leading companies in the Asia-Pacific generic injectables market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2017, Baxter International Inc. and ScinoPharm Taiwan, Ltd. announced a strategic partnership to develop, manufacture and commercialize 5 injectable drugs used in a variety of cancer treatments, including multiple myeloma, lung cancer, and breast cancer, also in medication to treat vomiting, nausea, and other common side effects of chemotherapy.
Asia-Pacific Generic Injectables Market, By Country, 2020 and 2028 (%)
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com